Akebia Therapeutics (AKBA) Short Interest Ratio & Short Volume

Short interest is the volume of Akebia Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 14,840,000 shares of AKBA short. Learn More on Akebia Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKBA shares currently have a short interest ratio of 8.0. Learn More on Akebia Therapeutics's short interest ratio.

Akebia Therapeutics saw a decline in short interest during the month of October. As of October 31st, there was short interest totaling 14,840,000 shares, a decline of 16.1% from the previous total of 17,680,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Akebia Therapeutics: UroGen Pharma Ltd. (28.14%), Puma Biotechnology, Inc. (9.07%), RAPT Therapeutics, Inc. (7.65%), Marinus Pharmaceuticals, Inc. (10.26%), ARS Pharmaceuticals, Inc. (25.60%), Day One Biopharmaceuticals, Inc. (26.44%), Evotec SE (0.08%), Praxis Precision Medicines, Inc. (9.99%), Arcus Biosciences, Inc. (13.82%), Gyre Therapeutics, Inc. (1.59%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling AKBA is an investing strategy that aims to generate trading profit from Akebia Therapeutics as its price is falling. AKBA shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Akebia Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AKBA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKBA, twice per month. The most recent reporting period available is October, 31 2024.